Evaluation of Interstitial Lung Disease Complications Caused by Biologic Agents Using a Spontaneous Adverse Drug Reaction Reporting Database
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Ayu Minagi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Pharmacy, Shujitsu University, Okayama, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Adverse Drug Reaction Reporting Systems, Biological Products, Biological Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Interstitial lung disease (ILD) is a clinically relevant adverse event associated with biologic agent use. However, the current incidence of ILD remains unclear as large‐scale risk assessments of biologic agents have not been conducted. The aim of this study was to clarify the association between biologic agent use and ILD development in clinical practice by detecting adverse event signals using a spontaneous adverse drug reaction database. The VigiBase database is used for spontaneous adverse event reporting. The analysis focused on nine biologics used to treat psoriasis, rheumatoid arthritis, and Crohn's disease. The safety of each biologic agent was evaluated using the information component signal detection method. There were 32,520,983 reports in VigiBase, of which 68,489 (0.21%) were for ILD. Signals were mainly detected for tumor necrosis factor‐α inhibitors when the information component for ILD caused by biologic agents was calculated. Comorbidity analysis in patients who developed ILD and analysis of the time from the start of treatment with each drug to ILD onset showed differences for each biologic agent. ILD is a serious adverse effect of biologic agents, and there are several cases in which a causal relationship with ILD development cannot be ruled out. The occurrence of interstitial ILD should be noted when using biologics, particularly TNF‐α inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Pharmacy, Shujitsu University, Okayama, Japan.
- Department of Pharmacy, Okayama University Hospital, Okayama, Japan.
- Department of Pharmacy, Okayama Kyokuto Hospital, Okayama, Japan.
- Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
- Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
ORCID-Profile: Ayu Minagi, Hideki Nawa, Mitsuhiro Goda
Förderung
- JSPS KAKENHI
Zitieren
APA
Minagi, A., Nawa, H., Goda, M., Niimura, T., Miyata, K., Hamano, H., Zamami, Y., & Ishizawa, K. (2025). Evaluation of Interstitial Lung Disease Complications Caused by Biologic Agents Using a Spontaneous Adverse Drug Reaction Reporting Database. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70063
Vancouver
Minagi A, Nawa H, Goda M, Niimura T, Miyata K, Hamano H, et al. Evaluation of Interstitial Lung Disease Complications Caused by Biologic Agents Using a Spontaneous Adverse Drug Reaction Reporting Database. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70063
BibTeX
@article{Minagi2025,
author = {Minagi, Ayu and Nawa, Hideki and Goda, Mitsuhiro and Niimura, Takahiro and Miyata, Koji and Hamano, Hirofumi and Zamami, Yoshito and Ishizawa, Keisuke},
title = {Evaluation of Interstitial Lung Disease Complications Caused by Biologic Agents Using a Spontaneous Adverse Drug Reaction Reporting Database},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70063}
}
EUVIMED